Spectrum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SPPI)

$20.92 1.89 (9.93 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$20.92
Today's Range$18.85 - $21.00
52-Week Range$4.31 - $21.95
Volume1.67 million shs
Average Volume919,314 shs
Market Capitalization$2.04 billion
P/E Ratio-20.92
Dividend YieldN/A
Beta1.63

About Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone+1-702-8356300

Debt

Debt-to-Equity Ratio0.33%
Current Ratio5.04%
Quick Ratio4.89%

Price-To-Earnings

Trailing P/E Ratio-20.92
Forward P/E Ratio-19.74
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.44 million
Price / Sales14.38
Cash FlowN/A
Price / CashN/A
Book Value$2.93 per share
Price / Book7.14

Profitability

Trailing EPS($1.00)
Net Income$-68,510,000.00
Net Margins-58.94%
Return on Equity-29.73%
Return on Assets-16.45%

Miscellaneous

Employees227
Outstanding Shares100,660,000

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced its earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.06. The biotechnology company had revenue of $36.40 million for the quarter, compared to analysts' expectations of $33.27 million. Spectrum Pharmaceuticals had a negative net margin of 58.94% and a negative return on equity of 29.73%. The company's revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.07) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

Where is Spectrum Pharmaceuticals' stock going? Where will Spectrum Pharmaceuticals' stock price be in 2018?

5 brokers have issued 12 month price objectives for Spectrum Pharmaceuticals' stock. Their predictions range from $11.00 to $32.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $24.60 in the next twelve months. View Analyst Ratings for Spectrum Pharmaceuticals.

What are Wall Street analysts saying about Spectrum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Spectrum Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "A BLA is expected to be filed in 2018 for the Spectrum's’s lead pipeline candidate, Rolontis. A potential approval will help the company compete better. However, Spectrum’s efforts to gain approval for Qapzola (bladder cancer) in the United States suffered a setback with the FDA issuing a CRL in November 2016. Additional regulatory/development setbacks could affect the stock. However, out-licensing agreements for a number of products will allow Spectrum to focus on Evomela and the development of its pipeline candidates. Spectrum’s shares have significantly outperformed the industry in past one year. However, Spectrum's low product sales remain a cause of concern. Moreover, gaining market share is challenging for Spectrum as it competes with several companies with greater financial strength. Estimates have remained stable ahead of the Q4 earnings results." (1/12/2018)
  • 2. Jefferies Group LLC analysts commented, "SPPI is undervalued based on Rolontis' LT promise in chemotherapy-induced neutropenia. We see 50%+ share upside as Rolontis' Ph. III program is lower risk (with data in H1 2018) and we believe its profile, senior management's oncology experience, and CIN market dynamics should enable Rolontis to gain meaningful market share from Neulasta. Poziotinib in mBC/NSCLC bears watching and offers pipeline optionality. Assume at Buy and $7.50 PT." (2/10/2017)

Who are some of Spectrum Pharmaceuticals' key competitors?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:

  • Stuart Mitchell Krassner, Chairman of the Board (Age 81)
  • Joseph W. Turgeon, President, Chief Executive Officer, Director (Age 59)
  • Kurt A. Gustafson, Chief Financial Officer, Executive Vice President (Age 49)
  • Thomas J. Riga, Chief Operating Officer
  • Luigi Lenaz M.D., Lead Independent Director (Age 76)
  • Gilles R. Gagnon, Director (Age 63)
  • Raymond Wayne Cohen, Independent Director (Age 58)
  • Anthony E. Maida III, Ph.D., Independent Director (Age 65)
  • Dolatrai Vyas Ph.D., Independent Director (Age 73)

Who owns Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Schwab Charles Investment Management Inc. (0.46%), Louisiana State Employees Retirement System (0.04%) and State of Alaska Department of Revenue (0.02%). View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Who sold Spectrum Pharmaceuticals stock? Who is selling Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Who bought Spectrum Pharmaceuticals stock? Who is buying Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and State of Alaska Department of Revenue. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy Spectrum Pharmaceuticals stock?

Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $20.92.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $2.04 billion and generates $146.44 million in revenue each year. The biotechnology company earns $-68,510,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Spectrum Pharmaceuticals employs 227 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 S Eastern Ave Ste 240, HENDERSON, NV 89052-5576, United States. The biotechnology company can be reached via phone at +1-702-8356300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (SPPI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  402
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spectrum Pharmaceuticals (NASDAQ:SPPI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.60$24.60$24.25$10.00
Price Target Upside: 29.20% upside29.20% upside28.31% upside56.25% upside

Spectrum Pharmaceuticals (NASDAQ:SPPI) Consensus Price Target History

Price Target History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2017HC WainwrightReiterated RatingBuy$29.00HighView Rating Details
12/18/2017B. RileyInitiated CoverageBuy -> Buy$26.00HighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$32.00N/AView Rating Details
10/20/2017Jefferies GroupBoost Price TargetBuy$25.00N/AView Rating Details
4/1/2017FBR & CoReiterated RatingBuyMediumView Rating Details
9/15/2016Royal Bank of CanadaSet Price TargetBuy$11.00 -> $10.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings History and Estimates Chart

Earnings by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ SPPI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.16)($0.22)$33.27 million$36.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.27)($0.26)$30.50 million$34.30 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.20)($0.18)$32.23 million$29.10 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.27)($0.22)$31.13 million$35.24 millionViewListenView Earnings Details
11/14/2016Q3 2016($0.30)($0.22)$29.53 million$33.39 millionViewN/AView Earnings Details
8/9/2016Q216($0.29)($0.05)$30.88 million$33.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.14)$28.83 million$43.90 millionViewN/AView Earnings Details
3/9/2016Q415($0.18)($0.06)$33.87 million$50.30 millionViewN/AView Earnings Details
11/4/2015Q315($0.25)($0.28)$31.87 million$28.46 millionViewN/AView Earnings Details
8/6/2015Q215($0.22)($0.01)$34.48 million$44.98 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$48.00 million$38.60 millionViewN/AView Earnings Details
3/13/2015Q414($0.16)$0.09$48.50 million$51.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)$0.08$45.00 million$47.99 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)$0.09$41.50 million$46.90 millionViewListenView Earnings Details
5/8/2014Q114($0.22)$0.01$39.49 million$40.10 millionViewListenView Earnings Details
3/6/2014Q313($0.11)$0.05$41.96 million$41.50 millionViewListenView Earnings Details
11/12/2013Q3($0.07)($0.13)$38.70 million$42.44 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.12)($0.08)$33.41 million$33.23 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.32)($0.06)$49.88 million$38.67 millionViewN/AView Earnings Details
2/21/2013Q4 2012$0.16$0.18ViewN/AView Earnings Details
11/7/2012Q312$0.29$0.42$68.56 million$69.00 millionViewN/AView Earnings Details
8/8/2012Q2 2012$0.31$0.34ViewN/AView Earnings Details
4/26/2012Q1 2012$0.28$0.35ViewN/AView Earnings Details
3/1/2012Q4 2011$0.28$0.13ViewN/AView Earnings Details
10/28/2011Q3 2011$0.09$0.29ViewN/AView Earnings Details
8/4/2011Q2 2011$0.13$0.13ViewN/AView Earnings Details
5/4/2011Q1 2011$0.01$0.33ViewN/AView Earnings Details
3/10/2011Q4 2010($0.04)$0.14ViewN/AView Earnings Details
11/4/2010Q3 2010($0.22)($0.07)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.15)($0.20)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.15)($0.78)ViewN/AView Earnings Details
4/5/2010Q4 2009($0.20)($0.19)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.20)($0.17)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.14)($0.28)ViewN/AView Earnings Details
5/18/2009Q1 2009($0.11)$0.02ViewN/AView Earnings Details
3/31/2009Q4 2008($0.17)($0.12)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.32)($0.28)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.34)$0.34ViewN/AView Earnings Details
5/13/2008Q1 2008($0.40)($0.28)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.38)($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.06 EPS
Next Year EPS Consensus Estimate: $-0.91 EPS

Dividends

Spectrum Pharmaceuticals (NASDAQ:SPPI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$0.1512/18/201212/20/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.33%
Institutional Ownership Percentage: 71.84%
Insider Trades by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Institutional Ownership by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/5/2013Anthony E Maida IIIDirectorSell5,000$12.25$61,250.00View SEC Filing  
11/12/2012Joseph Kenneth KellerCOOBuy10,000$10.95$109,500.00View SEC Filing  
11/1/2012Anthony E Maida IIIDirectorSell5,000$11.09$55,450.00View SEC Filing  
9/4/2012Anthony E Maida IIIDirectorSell5,000$12.01$60,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spectrum Pharmaceuticals (NASDAQ SPPI) News Headlines

Source:
DateHeadline
Spectrum Pharmaceuticals Up 134% in 6 Months: Heres Why - NasdaqSpectrum Pharmaceuticals Up 134% in 6 Months: Here's Why - Nasdaq
www.nasdaq.com - January 20 at 7:36 AM
Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS - PR Newswire (press release)Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS - PR Newswire (press release)
www.prnewswire.com - January 17 at 3:24 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from BrokeragesSpectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 16 at 5:34 PM
Spectrum Pharmaceuticals (SPPI) Raised to "Hold" at Zacks Investment ResearchSpectrum Pharmaceuticals (SPPI) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 12 at 9:38 PM
$33.05 Million in Sales Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter$33.05 Million in Sales Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter
www.americanbankingnews.com - January 9 at 3:02 PM
Spectrum Pharmaceuticals (SPPI) Downgraded by Zacks Investment ResearchSpectrum Pharmaceuticals (SPPI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
Spectrum Pharmaceuticals: Buy The Dip - Seeking AlphaSpectrum Pharmaceuticals: Buy The Dip - Seeking Alpha
seekingalpha.com - December 24 at 3:34 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $33.05 MillionSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $33.05 Million
www.americanbankingnews.com - December 23 at 5:00 AM
Stock Traders Buy Large Volume of Spectrum Pharmaceuticals Put Options (SPPI)Stock Traders Buy Large Volume of Spectrum Pharmaceuticals Put Options (SPPI)
www.americanbankingnews.com - December 23 at 2:52 AM
 Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Earnings of -$0.25 Per Share Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - December 21 at 5:10 PM
Spectrum Pharmaceuticals Inc (NASDAQ:SPPI): What Does The Future Look Like?Spectrum Pharmaceuticals Inc (NASDAQ:SPPI): What Does The Future Look Like?
finance.yahoo.com - December 21 at 7:57 AM
Spectrum Pharmaceuticals IncSpectrum Pharmaceuticals Inc
www.bloomberg.com - December 20 at 3:23 PM
B. Riley Initiates Coverage on Spectrum Pharmaceuticals (SPPI)B. Riley Initiates Coverage on Spectrum Pharmaceuticals (SPPI)
www.americanbankingnews.com - December 18 at 9:52 PM
Spectrum Pharma Dismisses CEO, Makes Leadership Changes ... - NasdaqSpectrum Pharma Dismisses CEO, Makes Leadership Changes ... - Nasdaq
www.nasdaq.com - December 18 at 3:23 PM
Spectrum Pharmaceuticals (SPPI) "Buy" Rating Reaffirmed at HC WainwrightSpectrum Pharmaceuticals' (SPPI) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - December 18 at 1:36 PM
Spectrum Pharmaceuticals Announces Leadership Changes - Business Wire (press release)Spectrum Pharmaceuticals Announces Leadership Changes - Business Wire (press release)
www.businesswire.com - December 18 at 7:35 AM
Pre-Market Technical Scan on Biotech Equities -- Spectrum Pharma, Jazz Pharma, Intra-Cellular Therapies, and Dermira - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Spectrum Pharma, Jazz Pharma, Intra-Cellular Therapies, and Dermira - PR Newswire (press release)
www.prnewswire.com - December 13 at 7:53 AM
Spectrum Pharma (SPPI) Announces Two Oral Presentations on FOLOTYN (Pralatrexate Injection) - StreetInsider.comSpectrum Pharma (SPPI) Announces Two Oral Presentations on FOLOTYN (Pralatrexate Injection) - StreetInsider.com
www.streetinsider.com - December 13 at 7:53 AM
Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)
finance.yahoo.com - December 13 at 7:53 AM
An Overview of Spectrum Pharmaceuticals’ Drug PipelineAn Overview of Spectrum Pharmaceuticals’ Drug Pipeline
finance.yahoo.com - December 12 at 3:23 PM
A Look at Spectrum Pharmaceuticals’ Recent AcquisitionsA Look at Spectrum Pharmaceuticals’ Recent Acquisitions
finance.yahoo.com - December 12 at 7:49 AM
Spectrum Pharmaceuticals’ Product Licensing AgreementsSpectrum Pharmaceuticals’ Product Licensing Agreements
finance.yahoo.com - December 12 at 7:49 AM
Stock Traders Purchase Large Volume of Spectrum Pharmaceuticals Call Options (SPPI)Stock Traders Purchase Large Volume of Spectrum Pharmaceuticals Call Options (SPPI)
www.americanbankingnews.com - December 8 at 1:32 AM
18 small-cap stocks that analysts expect to rise at least 50% in 201818 small-cap stocks that analysts expect to rise at least 50% in 2018
finance.yahoo.com - December 6 at 8:12 AM
Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology ... - Business Wire (press release)Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology ... - Business Wire (press release)
www.businesswire.com - December 4 at 7:41 AM
Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017
finance.yahoo.com - December 4 at 7:41 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by AnalystsSpectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 27 at 5:50 PM
Spectrum Doubles in 3 Months: Whats Driving the Rally?Spectrum Doubles in 3 Months: What's Driving the Rally?
finance.yahoo.com - November 27 at 4:11 PM
Financial Survey: Spectrum Pharmaceuticals (SPPI) versus Its CompetitorsFinancial Survey: Spectrum Pharmaceuticals (SPPI) versus Its Competitors
www.americanbankingnews.com - November 20 at 1:30 AM
Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad GeneticsToday’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad Genetics
finance.yahoo.com - November 18 at 8:57 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Earnings of -$0.25 Per ShareSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - November 15 at 11:41 AM
Why Spectrum Pharmaceuticals Stock Soared in OctoberWhy Spectrum Pharmaceuticals Stock Soared in October
www.fool.com - November 8 at 12:19 PM
Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates - NasdaqSpectrum (SPPI) Earnings, Sales Beat Q3 Estimates - Nasdaq
www.nasdaq.com - November 5 at 2:41 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Stock Rating Reaffirmed by HC WainwrightSpectrum Pharmaceuticals, Inc. (SPPI) Stock Rating Reaffirmed by HC Wainwright
www.americanbankingnews.com - November 4 at 11:32 PM
Spectrum Pharmaceuticals, Inc. to Host Earnings CallSpectrum Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 4 at 4:39 PM
Spectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline UpdateSpectrum Pharmaceuticals Reports Third Quarter 2017 Financial Results and Pipeline Update
finance.yahoo.com - November 4 at 4:39 PM
Spectrum Pharma reports 3Q lossSpectrum Pharma reports 3Q loss
finance.yahoo.com - November 4 at 4:38 PM
Edited Transcript of SPPI earnings conference call or presentation 2-Nov-17 8:30pm GMTEdited Transcript of SPPI earnings conference call or presentation 2-Nov-17 8:30pm GMT
finance.yahoo.com - November 4 at 4:38 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Issues  Earnings ResultsSpectrum Pharmaceuticals, Inc. (SPPI) Issues Earnings Results
www.americanbankingnews.com - November 3 at 4:02 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from AnalystsSpectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 2 at 9:44 PM
Spectrum Pharmaceuticals (SPPI) Q3 Earnings: Whats in Store?Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?
www.zacks.com - November 2 at 9:06 AM
Spectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and WebcastSpectrum Pharmaceuticals Announces Third Quarter 2017 Financial Results Teleconference and Webcast
finance.yahoo.com - October 28 at 6:55 AM
Short Interest in Spectrum Pharmaceuticals, Inc. (SPPI) Decreases By 18.1%Short Interest in Spectrum Pharmaceuticals, Inc. (SPPI) Decreases By 18.1%
www.americanbankingnews.com - October 27 at 1:40 AM
Zacks: Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Earnings of -$0.23 Per ShareZacks: Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - October 25 at 11:30 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Now Covered by Analysts at GuggenheimSpectrum Pharmaceuticals, Inc. (SPPI) Now Covered by Analysts at Guggenheim
www.americanbankingnews.com - October 23 at 6:50 PM
Critical Survey: Spectrum Pharmaceuticals (SPPI) vs. Its PeersCritical Survey: Spectrum Pharmaceuticals (SPPI) vs. Its Peers
www.americanbankingnews.com - October 22 at 8:20 AM
Jefferies Group LLC Raises Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $25.00Jefferies Group LLC Raises Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $25.00
www.americanbankingnews.com - October 21 at 2:58 PM
Spectrum Pharmaceuticals Inc. (SPPI) Leaped To A New High On Phase 2 Study NewsSpectrum Pharmaceuticals Inc. (SPPI) Leaped To A New High On Phase 2 Study News
www.rttnews.com - October 20 at 8:22 AM
Spectrum Pharmaceuticals Inc. (SPPI) Has Surged To A New High On Study Results - NasdaqSpectrum Pharmaceuticals Inc. (SPPI) Has Surged To A New High On Study Results - Nasdaq
www.nasdaq.com - October 19 at 9:10 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Receives Buy Rating from HC WainwrightSpectrum Pharmaceuticals, Inc. (SPPI) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - October 18 at 7:08 PM

SEC Filings

Spectrum Pharmaceuticals (NASDAQ:SPPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spectrum Pharmaceuticals (NASDAQ:SPPI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spectrum Pharmaceuticals (NASDAQ SPPI) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.